In prostate cancer, specific SPOP mutation can also confer resistance to BET-BD inhibitors through stabilization of BRD4 (Dai et al., 2017) and enhanced Akt–mTORC1 activation as a result of BRD4 stabilization (Zhang et al., 2017). This evidence concerns the gene BRD4 and prostate cancer.